Efficacy and Safety of Lebrikizumab in moderate to severe atopic Dermatitis: Results of two randomized, double-blind, placebo-controlled phase III Studies (ADvocate1 and ADvocate2) at 52 Weeks

被引：0
|
作者：
Blauvelt, A. [1 ]
Thyssen, J. P. [2 ]
Guttman-Yassky, E. [3 ]
Bieber, T. [4 ]
Serra-Baldrich, E. [5 ]
Simspon, E. [6 ]
Rosmarin, D. [7 ]
Diemert, S. [8 ]
Elmaraghy, H. [9 ]
Silverberg, J. [10 ]
机构：
[1] Oregon Med Res Ctr, Portland, OR USA
[2] Univ Copenhagen, Bispebjerg Hosp, Copenhagen, Denmark
[3] Icahn Sch Med Mt Sinai, New York, NY USA
[4] Univ Hosp Bonn, Bonn, Germany
[5] Hosp Santa Creu & Sant Pau, Barcelona, Spain
[6] Oregon Hlth & Sci Univ, Portland, OR USA
[7] Tufts Univ, Sch Med, Boston, MA USA
[8] Almirall Hermal GmbH, Reinbek, Germany
[9] Eli Lilly & Co, Indianapolis, IN USA
[10] George Washington Univ, Sch Med & Hlth Sci, Washington, OR USA
来源：
ALLERGOLOGIE | 2023年 / 46卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
P4.01
引用
收藏
页码：530 / 530
页数：1
相关论文
共 50 条
  • [21] Montelukast treatment of moderate to severe atopic dermatitis in adults: A randomized, double-blind, placebo-controlled trial
    Veien, NK
    Busch-Sorensen, M
    Stausbol-Gron, B
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 53 (01) : 147 - 149
  • [22] Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 2b trial
    Zhao, Yan
    Zhang, Jianzhong
    Yang, Bin
    Li, Jingyi
    Ding, Yangfeng
    Wu, Liming
    Zhang, Litao
    Wang, Jinyan
    Zhu, Xiaohong
    Zhang, Furen
    Tao, Xiaohua
    Li, Yumei
    Zhang, Chunlei
    Li, Linfeng
    Lu, Jianyun
    Diao, Qingchun
    Lu, Qianjin
    Man, Xiaoyong
    Li, Fuqiu
    Xia, Xiujuan
    Cheng, Hao
    Jia, Yingmin
    Zhao, Guoqing
    Yan, Jinchun
    Chen, Bo
    CHINESE MEDICAL JOURNAL, 2024, 137 (02) : 200 - 208
  • [23] Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 2b trial
    Zhao Yan
    Zhang Jianzhong
    Yang Bin
    Li Jingyi
    Ding Yangfeng
    Wu Liming
    Zhang Litao
    Wang Jinyan
    Zhu Xiaohong
    Zhang Furen
    Tao Xiaohua
    Li Yumei
    Zhang Chunlei
    Li Linfeng
    Lu Jianyun
    Diao Qingchun
    Lu Qianjin
    Man Xiaoyong
    Li Fuqiu
    Xia Xiujuan
    Cheng Hao
    Jia Yingmin
    Zhao Guoqing
    Yan Jinchun
    Chen Bo
    中华医学杂志英文版, 2024, 137 (02)
  • [24] Efficacy and safety of lebrikizumab combined with topical corticosteroids in Japanese patients with moderate-to-severe atopic dermatitis: a phase 3, double-blind, placebo-controlled, randomized clinical trial (ADhere-J)
    Katoh, Norito
    Tanaka, Akio
    Takahashi, Hidetoshi
    Shimizu, Ryosuke
    Kataoka, Yoko
    Torisu-Itakura, Hitoe
    Morisaki, Yoji
    Igawa, Ken
    CURRENT MEDICAL RESEARCH AND OPINION, 2025, 41 (01) : 1 - 12
  • [25] Efficacy and Safety of Lebrikizumab in Severe Uncontrolled Asthma: Results from the Lute and Verse Phase II Randomized, Double-Blind, Placebo-Controlled Trials
    Hanania, Nicola A.
    Noonan, Michael J.
    Corren, Jonathan
    Korenblat, Phillip
    Zheng, Yanan
    Putnam, Wendy
    Murray, Elaine
    Abelardo, Connie
    Scheerens, Heleen
    Maciuca, Romeo
    Gray, Sarah
    Doyle, Ramona
    McClintock, Dana
    Matthews, John G.
    Yen, Karl
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2014, 133 (02) : AB402 - AB402
  • [26] Efficacy and safety of oxycodone DETERx: results of a randomized, double-blind, placebo-controlled phase III study
    Kopecky, E.
    O'Connor, M.
    Varanasi, R.
    Saim, S.
    Fleming, A.
    JOURNAL OF PAIN, 2015, 16 (04): : S87 - S87
  • [27] Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from two phase III randomized double-blind studies
    Papp, K.
    Szepietowski, J. C.
    Kircik, L.
    Toth, D.
    Kuligowski, M. E.
    Venturanza, M.
    Sun, K.
    Simpson, E.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (04) : E116 - E117
  • [28] EFFICACY AND SAFETY OF CM310 IN MODERATE-TO-SEVERE ATOPIC DERMATITIS: RESULTS FROM A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2B TRIAL IN CHINA
    Zhang, Jianzhong
    Yang, Bin
    Li, Jingyi
    Ding, Yangfeng
    Wu, Liming
    Zhang, Litao
    Wang, Jinyan
    Zhu, Xiaohong
    Zhang, Furen
    Tao, Xiaohua
    Li, Yumei
    Zhang, Chunlei
    Li, Linfeng
    Lu, Jianyun
    Diao, Qingchun
    Lu, Qianjin
    Man, Xiaoyong
    Li, Fuqiu
    Xia, Xiujuan
    Cheng, Hao
    Zhao, Yan
    Chen, Bo
    Yan, Jinchun
    Zhao, Guoqing
    Jia, Yingmin
    ACTA DERMATO-VENEREOLOGICA, 2022, 102 : 20 - 20
  • [29] Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials
    Simpson, Eric L.
    Merola, Joseph F.
    Silverberg, Jonathan, I
    Reich, Kristian
    Warren, Richard B.
    Staumont-Salle, Delphine
    Girolomoni, Giampiero
    Papp, Kim
    de Bruin-Weller, Marjolein
    Thyssen, Jacob P.
    Zachariae, Rebecca
    Olsen, Christiana K.
    Wollenberg, Andreas
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (06) : 888 - 899
  • [30] Efficacy and Safety of Lebrikizumab in Combination with Topical Corticosteroids in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 3, Randomized, Placebo-Controlled Trial (ADhere)
    Simpson, Eric L.
    Gooderham, Melinda
    Wollenberg, Andreas
    Weidinger, Stephan
    Armstrong, April
    Soung, Jennifer
    Ferrucci, Silvia
    Lima, Renata Gontijo
    Xu, Wen
    Witte, Michael M.
    Blauvelt, Andrew
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 61 - 61
12345